These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22510149)

  • 21. MYC/BCL2 double-hit high-grade B-cell lymphoma.
    Li S; Lin P; Young KH; Kanagal-Shamanna R; Yin CC; Medeiros LJ
    Adv Anat Pathol; 2013 Sep; 20(5):315-26. PubMed ID: 23939148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
    Johnson NA; Savage KJ; Ludkovski O; Ben-Neriah S; Woods R; Steidl C; Dyer MJ; Siebert R; Kuruvilla J; Klasa R; Connors JM; Gascoyne RD; Horsman DE
    Blood; 2009 Sep; 114(11):2273-9. PubMed ID: 19597184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations.
    Niitsu N; Okamoto M; Miura I; Hirano M
    Leukemia; 2009 Apr; 23(4):777-83. PubMed ID: 19151788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
    Miyamoto K; Kobayashi Y; Maeshima AM; Taniguchi H; Nomoto J; Kitahara H; Fukuhara S; Munakata W; Maruyama D; Tobinai K
    Int J Hematol; 2016 Jun; 103(6):693-702. PubMed ID: 27095041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation.
    Sevilla DW; Gong JZ; Goodman BK; Buckley PJ; Rosoff P; Gockerman JP; Lagoo AS
    Am J Clin Pathol; 2007 Dec; 128(6):981-91. PubMed ID: 18024324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "Double-Hit" mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression.
    Wu D; Wood BL; Dorer R; Fromm JR
    Am J Clin Pathol; 2010 Aug; 134(2):258-65. PubMed ID: 20660329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
    Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
    J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
    Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
    Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-hit B-cell lymphomas.
    Aukema SM; Siebert R; Schuuring E; van Imhoff GW; Kluin-Nelemans HC; Boerma EJ; Kluin PM
    Blood; 2011 Feb; 117(8):2319-31. PubMed ID: 21119107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.
    Lucioni M; Pescia C; Bonometti A; Fraticelli S; Moltrasio C; Ramponi A; Riboni R; Roccio S; Ferrario G; Arcaini L; Goteri G; Berti E; Paulli M
    Hum Pathol; 2021 May; 111():1-9. PubMed ID: 33548250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.
    Landsburg DJ; Nasta SD; Svoboda J; Morrissette JJ; Schuster SJ
    Br J Haematol; 2014 Aug; 166(3):369-74. PubMed ID: 24761809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. t(14;18)(q32;q21) involving IGH and MALT1 is uncommon in cutaneous MALT lymphomas and primary cutaneous diffuse large B-cell lymphomas.
    Wongchaowart NT; Kim B; Hsi ED; Swerdlow SH; Tubbs RR; Cook JR
    J Cutan Pathol; 2006 Apr; 33(4):286-92. PubMed ID: 16630178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.
    Cucco F; Barrans S; Sha C; Clipson A; Crouch S; Dobson R; Chen Z; Thompson JS; Care MA; Cummin T; Caddy J; Liu H; Robinson A; Schuh A; Fitzgibbon J; Painter D; Smith A; Roman E; Tooze R; Burton C; Davies AJ; Westhead DR; Johnson PWM; Du MQ
    Leukemia; 2020 May; 34(5):1329-1341. PubMed ID: 31844144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary Mediastinal Large B-Cell Lymphoma With Translocations Involving BCL6 and MYC (Double-Hit Lymphoma).
    Campuzano-Zuluaga G; Ortiz D; Peng JH; Francis Ikpatt O; Fan YS; Barredo JC; Vega F; Chapman JR
    Am J Clin Pathol; 2016 May; 145(5):710-6. PubMed ID: 27124935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.
    Li S; Seegmiller AC; Lin P; Wang XJ; Miranda RN; Bhagavathi S; Medeiros LJ
    Mod Pathol; 2015 Feb; 28(2):208-17. PubMed ID: 25103070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
    Barrans SL; Evans PA; O'Connor SJ; Kendall SJ; Owen RG; Haynes AP; Morgan GJ; Jack AS
    Clin Cancer Res; 2003 Jun; 9(6):2133-9. PubMed ID: 12796378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.
    Caponetti GC; Dave BJ; Perry AM; Smith LM; Jain S; Meyer PN; Bast M; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Aoun P; Fu K; Greiner TC; Chan WC; Sanger WG; Weisenburger DD
    Leuk Lymphoma; 2015; 56(11):3082-9. PubMed ID: 25827211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
    Kobayashi T; Tsutsumi Y; Sakamoto N; Nagoshi H; Yamamoto-Sugitani M; Shimura Y; Mizutani S; Matsumoto Y; Nishida K; Horiike S; Asano N; Nakamura S; Kuroda J; Taniwaki M
    Jpn J Clin Oncol; 2012 Nov; 42(11):1035-42. PubMed ID: 22984125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.